Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT01949311) enrolled 2,677 people, all of whom received the medicine dupilumab. The trial was a single-group study — meaning there was no separate comparison or placebo group — and it was primarily focused on tracking adverse events (that is, any unwanted medical occurrences that happened during the study period). Of the 2,677 people who started, 1,297 completed the study, while 1,380 did not complete it; the reasons for not completing were not detailed in the data provided here. The reported data shows that across all participants, 14,717 treatment-emergent adverse events (meaning unwanted medical occurrences that happened after starting the treatment) were recorded in total. The trial also specifically tracked certain pre-defined "adverse events of special interest" — a set of particular medical events including serious allergic reactions, certain eye conditions, and some types of infections. According to the results reported on ClinicalTrials.gov, 161 of these special-interest events were recorded across the group, at a rate of approximately 2.76 such events per person per year. Nine of these special-interest events were classified as serious. An optional sub-study looking at these same special-interest events after participants switched to a new version of the dupilumab product reported zero such events, though the size of that sub-group was not detailed in the submitted data. The reported data also includes a skin severity score called the IGA (Investigator's Global Assessment), which rates skin condition on a scale from 0 (clear) to 4 (severe). At the start of the study, 12% of participants had a score of 0 or 1 (clear or almost clear skin). Across later check-in points, that percentage was reported to rise, reaching as high as 81.2% at one recorded visit, though the timing of each individual measurement was not fully detailed in the submitted data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 41999446) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Eczema Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You previously took part in a clinical trial of dupilumab for eczema (atopic dermatitis) and completed the required visits and assessments in that trial
- You previously received dupilumab in a specific type of trial that has finished, even if you didn't participate for the full duration, as long as you followed the instructions given during that study
- You went through the screening process for one of two specific dupilumab trials (Liberty AD SOLO 1 or SOLO 2) but were unable to be assigned to a treatment group because the trial closed enrollment before you could join
- You are willing and able to attend all clinic visits and follow all study procedures
- You are able to understand and fill out study questionnaires
- You are able to sign a consent form agreeing to take part
For the optional part of the study, you must also:
- Be willing to sign a separate consent form for that part
- Still be in the active treatment phase of the main study
- Have shown that you have been taking dupilumab as instructed (confirm with trial site)
Who may not be able to join:
- You had a serious side effect during a previous dupilumab trial that was believed to be caused by dupilumab, and the doctor feels that continuing the treatment could put you at unreasonable risk
- You had a side effect in a previous dupilumab trial that was believed to be caused by dupilumab and led to you stopping the treatment, and the doctor feels continuing could be unsafe for you
- You had a condition during a previous dupilumab trial that required you to permanently stop the study drug, or you were withdrawn from the study — for example, due to not following the study rules or being unable to complete the required assessments
- You have taken another experimental drug (other than dupilumab) within the past 8 weeks, or within 5 times that drug's clearance time from the body (whichever is longer), before the start of this study
- You are currently pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study
For the optional part of the study, you may not be able to join if:
- You have already completed the final treatment visit for the main related study (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trial Management, Regeneron Pharmaceuticals
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
8 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of Treatment Emergent Adverse Events (TEAEs); OPTIONAL SUB-STUDY: Number of Adverse Events of Special Interest (AESIs) Through the Last Study Visit After Switching to the New Dupilumab Drug Product
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.